Honz Pharmaceutical Co Ltd

Honz Pharmaceutical Co Ltd has a market capitalization of 3.05 billion CNY and a price-to-book ratio of 3.39, indicating that the market values the company at a premium to its book value. The company's liquidity position is characterized as medium risk, with a current ratio of 0.52, suggesting that it may struggle to meet short-term obligations with its current assets. Free cash flow is negative at -275.59 million CNY, and capital expenditures are -92.12 million CNY, indicating that the company is investing in its operations but is not generating sufficient cash to cover these expenses.

Profitability metrics show a challenging financial position for Honz Pharmaceutical Co Ltd. The company reported a net loss of 230.14 million CNY and an operating loss of 257.32 million CNY, with a return on equity of -25.58% and a return on assets of -12.85%. These figures are below the industry median for profitability, as the pharmaceutical sector typically maintains positive returns on equity and assets. The company's gross profit of 244.89 million CNY is also underperforming relative to its revenue of 466.12 million CNY, indicating margin compression or high cost of goods sold.

Geographically, Honz Pharmaceutical Co Ltd is primarily focused on the Chinese market, with no disclosed international revenue segments. The company's revenue concentration in a single geographic region exposes it to regulatory, economic, and geopolitical risks specific to China. There are no disclosed segments or product lines that contribute to revenue diversification.

The company's growth trajectory is mixed. While the most recent actual revenue was reported at 882.74 million CNY, the company's net loss and negative operating income suggest that it is not currently generating sufficient earnings to support growth. The outlook for the current fiscal year is uncertain, with no clear direction provided in the available data. The company's debt-to-equity ratio of 0.63 indicates a moderate level of leverage, but the negative net cash position raises concerns about its ability to service debt obligations.

Risk factors for Honz Pharmaceutical Co Ltd include liquidity constraints, as the company has negative net cash after subtracting total debt. The risk of dilution is currently low, but the company's negative free cash flow and high capital expenditures may necessitate future equity or debt financing, which could dilute existing shareholders. The company's financial performance and risk profile suggest that it is in a period of financial stress, with potential for further deterioration if operating losses continue.

Recent events and filings indicate that the company is under pressure to improve its financial performance. The most recent actual revenue figure of 882.74 million CNY is significantly higher than the previously reported revenue of 466.12 million CNY, suggesting a possible discrepancy or a change in reporting periods. The company's financial statements and disclosures should be closely monitored for further clarity on its financial position and strategic direction.